Phosphodiesterase 4D isoform 7 (PDE4D7)

Phosphodiesterase 4D isoform 7 (PDE4D7) is a long isoform of the cAMP-specific phosphodiesterase 4D enzyme, characterized by a unique N-terminal sequence and the presence of regulatory UCR1 and UCR2 domains [1, 13]. It plays a critical role in the spatial and temporal regulation of intracellular cAMP levels, which is essential for proper signal transduction and cellular homeostasis [2, 8]. In the context of oncology, PDE4D7 is a significant prognostic biomarker for prostate cancer; its downregulation is strongly associated with disease progression, increased risk of recurrence, and the development of androgen independence [6, 11]. The specific variant PDE4D7-S129D is a mutationally activated form of the enzyme where Serine 129 in the UCR1 domain is replaced by Aspartic acid to mimic phosphorylation by Protein Kinase A (PKA) [1, 3]. This phosphomimetic mutation increases the enzyme's hydrolytic activity and is a vital tool in drug discovery for screening subtype-selective allosteric inhibitors [4, 14]. Such inhibitors, including BPN14770, are being investigated for their potential to treat neurodevelopmental and neuropsychiatric disorders like Fragile X syndrome and Alzheimer's disease while avoiding the emetic side effects common to non-selective PDE4 inhibition [5, 7, 12].

Other names

cAMP-specific 3',5'-cyclic phosphodiesterase 4D isoform 7PDE4D7-S129DPhosphomimetic PDE4D7Activated PDE4D7

Inhibition of cAMP hydrolysis and allosteric modulation of the PDE4D enzyme to stabilize the closed, inactive conformation.